Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry; Big MS Data Network. Lorscheider J, et al. Among authors: benkert p. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39643429 Free article.
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo N, Benkert P, Sastre-Garriga J, Mongay-Ochoa N, Vilaseca-Jolonch A, Llufriu S, Blanco Y, Hegen H, Berek K, Perez-Miralles F, Rejdak K, Villar LM, Monreal E, Alvarez-Lafuente R, Soylu OK, Abdelhak A, Bachhuber F, Tumani H, Martínez-Yélamos S, Sánchez-López AJ, García-Merino A, Gutiérrez L, Castillo-Trivino T, Lycke J, Rosenstein I, Furlan R, Filippi M, Téllez N, Ramió-Torrentà L, Lünemann JD, Wiendl H, Eichau S, Khalil M, Kuhle J, Montalban X, Comabella M. Fissolo N, et al. Among authors: benkert p. J Neurol Neurosurg Psychiatry. 2024 Apr 12;95(5):410-418. doi: 10.1136/jnnp-2023-332251. J Neurol Neurosurg Psychiatry. 2024. PMID: 37940409
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Müller J, Roos I, Kalincik T, Lorscheider J, Galli E, Benkert P, Schädelin S, Sharmin S, Einsiedler M, Hänni P, Schmid J, Kuhle J, Derfuss T, Granziera C, Ziemssen T, Siepmann T, Yaldizli Ö. Müller J, et al. Among authors: benkert p. Brain Behav. 2024 May;14(5):e3498. doi: 10.1002/brb3.3498. Brain Behav. 2024. PMID: 38688877 Free PMC article.
Synthesizing cross-design evidence and cross-format data using network meta-regression.
Hamza T, Chalkou K, Pellegrini F, Kuhle J, Benkert P, Lorscheider J, Zecca C, Iglesias-Urrutia CP, Manca A, Furukawa TA, Cipriani A, Salanti G. Hamza T, et al. Among authors: benkert p. Res Synth Methods. 2023 Mar;14(2):283-300. doi: 10.1002/jrsm.1619. Epub 2023 Feb 22. Res Synth Methods. 2023. PMID: 36625736 Free article.
123 results